Skip to main content
Clinical Trials/NCT00257751
NCT00257751
Completed
Not Applicable

Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving

Oslo University Hospital0 sites400 target enrollmentMarch 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Oslo University Hospital
Enrollment
400
Primary Endpoint
Perioperative bleeding
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI. An increasing number of patients are referred to emergent or urgent CABG, and several studies, as well as our own experience, have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following CABG.

Detailed Description

Aprotinine (Trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. The most commeon practice is to give Trasylol in high doses immediately before surgery, during the operation, and during the first postoperative hours. However, it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively, but this remains unclear.

Registry
clinicaltrials.gov
Start Date
March 2004
End Date
November 2007
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Oslo University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Perioperative bleeding

Blood transfusions

Reoperation

Secondary Outcomes

  • Difference in costs related to low/high dose

Similar Trials